Loading...
Can cost affect the response to a Parkinson disease (PD) drug? Investigators conducted a small, prospective, double-blind study to answer this question. Twelve patients with moderate PD who were experiencing motor fluctuations were randomized to two placebo (saline) injections, given in random succession, and told one was a cheap therapy and the other an expensive, subcutaneous, novel, injectable dopamine agonist. At baseline, all subjects had on/off dopaminergic testing and subsequently underwent similar study procedures. The patients were given different descriptions of manufacturing cost prior to the injections. Four hours following the first injection, patients crossed over to the alternate group. Patients completed blinded assessments,…